These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 31824468)

  • 21. Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems.
    Shmakov S; Abudayyeh OO; Makarova KS; Wolf YI; Gootenberg JS; Semenova E; Minakhin L; Joung J; Konermann S; Severinov K; Zhang F; Koonin EV
    Mol Cell; 2015 Nov; 60(3):385-97. PubMed ID: 26593719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cas9 interaction with the tracrRNA nexus modulates the repression of type II-A CRISPR-cas genes.
    Kim H; Marraffini LA
    Nucleic Acids Res; 2024 Sep; 52(17):10595-10606. PubMed ID: 38994567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CRISPR-Cas effector specificity and cleavage site determine phage escape outcomes.
    Schelling MA; Nguyen GT; Sashital DG
    PLoS Biol; 2023 Apr; 21(4):e3002065. PubMed ID: 37058530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of CRISPR/cas system in the development of bacteriophage resistance.
    Szczepankowska A
    Adv Virus Res; 2012; 82():289-338. PubMed ID: 22420856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA interference is controlled by R-loop length in a type I-F1 CRISPR-Cas system.
    Tuminauskaite D; Norkunaite D; Fiodorovaite M; Tumas S; Songailiene I; Tamulaitiene G; Sinkunas T
    BMC Biol; 2020 Jun; 18(1):65. PubMed ID: 32539804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Advances in CRISPR/Cas9-mediated gene editing].
    Li C; Cao W
    Sheng Wu Gong Cheng Xue Bao; 2015 Nov; 31(11):1531-42. PubMed ID: 26939437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A genomic sequence of the type II-A clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated system in
    Mizuki H; Shimoyama Y; Ishikawa T; Sasaki M
    J Oral Microbiol; 2022; 14(1):2008153. PubMed ID: 34992734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA and RNA interference mechanisms by CRISPR-Cas surveillance complexes.
    Plagens A; Richter H; Charpentier E; Randau L
    FEMS Microbiol Rev; 2015 May; 39(3):442-63. PubMed ID: 25934119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CaSilico: A versatile CRISPR package for
    Asadbeigi A; Norouzi M; Vafaei Sadi MS; Saffari M; Bakhtiarizadeh MR
    Front Bioeng Biotechnol; 2022; 10():957131. PubMed ID: 36017348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CRISPR-Cas systems and RNA-guided interference.
    Barrangou R
    Wiley Interdiscip Rev RNA; 2013; 4(3):267-78. PubMed ID: 23520078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and Evolution of Cas9 tracrRNAs.
    Dooley SK; Baken EK; Moss WN; Howe A; Young JK
    CRISPR J; 2021 Jun; 4(3):438-447. PubMed ID: 34152211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CRISPR-Cas in Streptococcus pyogenes.
    Le Rhun A; Escalera-Maurer A; Bratovič M; Charpentier E
    RNA Biol; 2019 Apr; 16(4):380-389. PubMed ID: 30856357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mycobacterium tuberculosis type III-A CRISPR/Cas system crRNA and its maturation have atypical features.
    Wei W; Zhang S; Fleming J; Chen Y; Li Z; Fan S; Liu Y; Wang W; Wang T; Liu Y; Ren B; Wang M; Jiao J; Chen Y; Zhou Y; Zhou Y; Gu S; Zhang X; Wan L; Chen T; Zhou L; Chen Y; Zhang XE; Li C; Zhang H; Bi L
    FASEB J; 2019 Jan; 33(1):1496-1509. PubMed ID: 29979631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterizing the activity of abundant, diverse and active CRISPR-Cas systems in lactobacilli.
    Crawley AB; Henriksen ED; Stout E; Brandt K; Barrangou R
    Sci Rep; 2018 Aug; 8(1):11544. PubMed ID: 30068963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determining the Specificity of Cascade Binding, Interference, and Primed Adaptation
    Cooper LA; Stringer AM; Wade JT
    mBio; 2018 Apr; 9(2):. PubMed ID: 29666291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification and functional study of type III-A CRISPR-Cas systems in clinical isolates of Staphylococcus aureus.
    Cao L; Gao CH; Zhu J; Zhao L; Wu Q; Li M; Sun B
    Int J Med Microbiol; 2016 Dec; 306(8):686-696. PubMed ID: 27600408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spacer prioritization in CRISPR-Cas9 immunity is enabled by the leader RNA.
    Liao C; Sharma S; Svensson SL; Kibe A; Weinberg Z; Alkhnbashi OS; Bischler T; Backofen R; Caliskan N; Sharma CM; Beisel CL
    Nat Microbiol; 2022 Apr; 7(4):530-541. PubMed ID: 35314780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Different Target Sequences on Type III CRISPR-Cas Immunity.
    Maniv I; Jiang W; Bikard D; Marraffini LA
    J Bacteriol; 2016 Jan; 198(6):941-50. PubMed ID: 26755632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engineered CRISPR-Cas9 nucleases with altered PAM specificities.
    Kleinstiver BP; Prew MS; Tsai SQ; Topkar VV; Nguyen NT; Zheng Z; Gonzales AP; Li Z; Peterson RT; Yeh JR; Aryee MJ; Joung JK
    Nature; 2015 Jul; 523(7561):481-5. PubMed ID: 26098369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.
    Jinek M; Chylinski K; Fonfara I; Hauer M; Doudna JA; Charpentier E
    Science; 2012 Aug; 337(6096):816-21. PubMed ID: 22745249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.